Conflict Of Interest Reform Fight Reignites Following Panel Revelations
This article was originally published in The Tan Sheet
Executive Summary
Advisory committee conflict of interest reform draws increased attention in the wake of concerns raised about a recent Reproductive Health panel meeting.
You may also be interested in...
FDA Advisory Committees Would Get Patient Influence Under Hagan Bill
Adjusting advisory committee conflict of interest rules becomes a high-priority issue in reauthorizing FDA’s drug user fee program. With several bills proposing to loosen the rules, Sen. Hagan’s draft FDA reform legislation could bring the most changes.
For Biosimilars, A Mid-Review Cycle Product Quality Discussion Appears To Be A Bad Omen
Only about one-third of biosimilars received a first-cycle approval from US FDA after product quality discussions during the mid-assessment-cycle meeting, according to an interim report on the biosimilar application review program.
ANDA Submissions Drop To Start FY2021
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: